Travere Therapeutics (TVTX) Receivables - Net (2014 - 2026)

Travere Therapeutics' Receivables - Net history runs 13 years deep, the most recent figure standing at $87.3 million for Q1 2026.

• Quarterly Receivables - Net rose 153.78% year-over-year to $87.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.3 million (up 153.78% YoY) and the FY2025 annual result came in at $80.1 million, up 195.52% from the prior year.
• Receivables - Net was $87.3 million for Q1 2026 at Travere Therapeutics, up from $80.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $87.3 million in Q1 2026 and bottomed at $12.7 million in Q3 2022.
• A 5-year average of $33.0 million and a median of $22.7 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net decreased 5.22% — and 2025, when it soared 229.37%.
• Travere Therapeutics' Receivables - Net stood at $16.6 million in 2022, then increased by 27.23% to $21.2 million in 2023, then grew by 28.03% to $27.1 million in 2024, then jumped by 195.52% to $80.1 million in 2025, then gained by 8.94% to $87.3 million in 2026.
• Business Quant data shows TVTX's Receivables - Net at $87.3 million in Q1 2026, $80.1 million in Q4 2025, and $83.0 million in Q3 2025.